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Abstract
Upstream therapy is the promising issue in the treatment of atrial fibrillation (AF) especially
in patients with arterial hypertension and heart failure. The possible beneficial effects of renin–
–angiotensin–aldosterone system blockade with ACE-inhibitors and angiotensin receptor an-
tagonists in AF prevention have been demonstrated in experimental and clinical studies.
There is growing mass of evidence, from both theoretical and experimental research studies, to
suggest that upstream therapy using spironolactone or eplerenone may reduce the deleterious
effect of excess aldosterone secretion and further modify the environment of AF including
inhibition of atrial muscle fibrosis. It refers to patients with different forms of AF, including
chronic AF. Aldosterone antagonists treatment may be a simple and valuable additional
option in low-risk, hypertensive and heart failure patients in primary and secondary preven-
tion of refractory paroxysmal and persistent AF. (Cardiol J 2012; 19, 3: 223–229)
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Introduction
Recent years have verified rather negatively
the effectiveness of antiarrhythmic drugs in long-
term prevention of atrial fibrillation (AF) episodes.
One of the most relevant and promising issue is
“upstream therapy” and the search for triggers of
arrhythmia to treat the potential mechanisms of
rhythm disturbances. Although invasive electro-
physiology has made a great progress in the diag-
nosis and treatment of arrhythmias including AF,
it is a limited option in the large population of AF
patients. Its efficiency in longer perspective is still
not fully established. Therefore, it seems important
to search for new therapeutic methods that are in-
expensive, non-invasive, well tolerated and espe-
cially may help to prevent recurrences of AF.
According to the experimental study by Wijffels
et al. [1] ,,AF begets AF”, after arrhythmia occur-
rence electrical, neurohormonal and structural re-
modeling begin and risk of further arrhythmia per-
sistence increases. In the course of electrical re-
modeling, atrial effective refractory period (AERP)
is reduced. Its association with heart rate decreas-
es due to action potential reduction (diminution of
calcium channels type L activity even up to 70%)
[2]. AERP reduction creates conducive conditions
of re-entry circuit formation. Reduction of repolari-
zations of Ito potassium currents and amplification
of depolarization of INa and INCX currents takes place
[3]. Modifications of inward rectifier potassium cur-
rents IK1 and nerve vagus activated currents IKAch,
acetylocholine dependent, have been reported [4].
The function of these currents regulates resting
potential values [5]. Electrical remodeling of the
sinus node is reflected by longer pauses after con-
version to sinus rhythm. At the same time neuro-
hormonal early changes occur: growing concentra-
tions of atrial (ANP) and B-type (BNP) natriuretic
peptides, angiotensin II (ANG II), aldosterone (ALD),
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epinephrine [6, 7]. Structural remodeling conse-
quences are atrial enlargement, miocytes hypertro-
phy, contractility impairment and promotion of fi-
brosis. Interstitial fibrosis is a significant substrate
of arrhythmia, especially in patients with conges-
tive heart failure (HF). It’s preceded by growing ac-
tivity of matrix metalloproteinases and proinflam-
matory cytokines, like growing factor beta-1. Simul-
taneously more pronounced collagen I and III
expression, ”up-regulation’’ of metalloproteinases-2
and ”down-regulation” of tissue inhibitor metallo-
proteinase-1 (TIMP-1) occur [8, 9].
Theoretical considerations of
RAAS blockade in atrial fibrillation
Nakashima et al. in experimental studies de-
monstrated ANG II effect on atrial electrical remo-
deling: increased calcium channels L ion current
due to activation of protein kinase C and phosphoryla-
tion of these channels [10, 11]. Additionally, inhibi-
tion of potassium currents occurs which has an ad-
verse impact on the level of the action potential
plateau and repolarization [12]. ANG II also inhi-
bits conduction in the atrioventricular node, which
can cause increased risk of ventricular arrhythmias
in the mechanism of reentry [13]. Another adverse
effect of ANG II is the increased release of norepi-
nephrine from atrial sympathetic nerves through
the activation of nodal AT-1 receptors and a reduc-
tion of beta-adrenergic receptors density. This is
a proof of the interdependence between the adren-
ergic and renin–angiotensin–aldosteron-system
(RAAS) [14, 15]. ANG II also activates fibroblasts
and promotes the synthesis of growth factor beta-1
(TGF-beta-1). This leads to accumulation of col-
lagen and further structural transformation of the
heart. Progress of interstitial changes provoked by
MAP kinase increases the risk of AF. Finally, in-
creased expression of cardiac ANG II causes atrial
enlargement and fibrosis [9]. Table 1 presents the
most important mechanisms responsible for proar-
rhythmic actions of ANG II. Proarrhythmic effects
of ANG II and ALD are sufficiently documented in
experimental studies and they are responsible for
structural, neurohormonal and electrical remode-
ling of the atria [10, 16]. High activity of ANG II and
ALD promotes fibroblasts activation and collagen
accumulation that lead to structural changes in the
heart muscle. The role of the RAAS overactivity
mechanisms in AF promotion has been sufficiently
documented [9].
ANG II stimulates ALD synthesis in the zona
glomerulosa of the adrenal cortex via ALD synthase.
Other important factors stimulating ALD synthe-
sis are corticotrophin, endothelin, adrenalin, argin-
ine vasopressin, serotonin, nitrogen oxide and po-
tassium concentration [17–20]. ALD enhances the
effects of ANG II in part via increased transcription
of AT-1 receptor and ACE, whereas ANG II may
increase systemic and tissue concentrations of
ALD, consistently with elevated plasma levels of
both ANG II and ALD during AF [16]. ALD induc-
es cell proliferation and myocardial fibrosis possi-
bly due to an increase in the quantity of AT-1-
-receptors and enhanced local expression of the
angiotensin converting enzyme [18, 21, 22]. In
experimental studies, apart from its hypertensive
action, ALD significantly influenced the promotion
of hypertrophy, fibrosis, and necrosis of cardiomyo-
cytes, endothelium and vessel wall cells. ALD stimu-
lates collagen I, III synthesis and fibroblasts by ac-
tivating mineralocorticoid local receptors (MR). It
also promotes inflammatory processes, oxidative
stress, autonomic system dysfunction, necrosis of
atrial myocytes and vascular damage [18, 21–23].
ALD receptors were identified in the endothelium,
left ventricle, brain, kidneys, colon, salivary and
sweat glands. ALD can be synthetized locally as well
in the brain, heart and blood vessels [19, 20]. Oth-
er potentially arrhythmogenic mechanisms of ALD
actions include inhibition of noradrenaline reuptake,
attenuation of baroreceptor activity, increase of
their sensitivity to catecholamines and reduction of
sinus rhythm variability. A significant loss of potas-
sium and magnesium is also important [17, 23]. Tsai
et al. [24] have measured ALD levels and expres-
sion of steroidogenesis proteins in atrial tissue,
obtained from patients with and without AF during
surgery. Patients with AF had increased expression
of the atrial mineralocorticoid receptor as compared
Table 1. Proarrhythmic action of angiotensin II.
Activation of calcium currents through L channels
Inhibition of potassium currents
Inhibition of conduction in atrio-ventricular node
Increased release of norepinephrine from atrial
sympathetic nerves
Reduction of beta-adrenergic receptors density
Systemic pro-inflammatory and hypercoagulation
effects
Fibroblasts activation, increase of collagen
synthesis (MAP kinase)
Cardiac hypertrophy and fibrosis
Structural remodeling of atria and ventricles
Dilatation of atria and ventricles
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to patients with sinus rhythm. It is possible that the
effects of ALD in the atria are not due to the amount
of hormone that is generated locally, but might de-
pend from an increased tissue expression of mine-
ralocorticoid receptors (MR). Another study dem-
onstrated that expression of MR is increased by
sustained electrical field depolarization, and that
exposure of cells to ALD activates the inward cal-
cium and outward potassium current. In these in-
vitro experiments, co-incubation with spironolac-
tone (SPIR) attenuated the changes induced by
exposure of atrial cells to ALD, indicating the in-
volvement of a MR-dependent pathway. These find-
ings help promote understanding of the cellular and
electrophysiological mechanisms that might ac-
count for the beneficial effects of SPIR in the pre-
vention of AF (Table 2) [25].
Clinical evidence for RAAS inhibitors
in the prevention of atrial fibrilation
The beneficial effects of angiotensin convert-
ing enzyme inhibitors (ACE-I) and angiotensin re-
ceptor blockers (ARB) are mainly due to inhibition
of ANG II action, with directly results in blood pres-
sure reduction, improvement of the large vessels
distensibility, reduction of hypertrophy and preven-
tion of left ventricular remodeling. This leads to
a reduction in afterload and systolic left ventricular
strain. In addition, blood pressure is reduced, as well
as atrial wall strain and the degree of mitral regur-
gitation. The amount of catecholamines in the blood
and myocardium is reduced, but the concentrations
of bradykinin and prostaglandins are growing. ACE-I
increase parasympathetic activity and inhibits the
activity of ALD [9]. It has been shown that these
drugs have anti-inflammatory and antioxidant pro-
perties. In patients with permanent AF, ACE-I re-
duces the expression of Erk1/Erk2 protein kinases
which activates the fibrosis process [16]. In retro-
spective, but especially in prospective studies,
treatment with ACE-I reduced the recurrence of
persistent and paroxysmal AF [26–29]. On the con-
trary the GISSI-AF prospective study revealed that
one-year treatment with valsartan was not associ-
ated with a reduction in the incidence of recurrent
AF [30]. ALD antagonists, ACE-I and ARB, have
an additional antiarrhythmic potential and could be
used in the treatment and prevention of AF. Results
of experimental studies have revealed that enala-
pril decreases atrial fibrosis and structural remod-
eling and reduces the risk of AF in HF as well [31].
Analysis of 4,661 patients with AF, from a popula-
tion of 682,993 patients treated for hypertension,
revealed that long-term therapy with RAAS inhibi-
tors ACE-I, ARB and beta-blockers, were associat-
ed with a lower risk for AF [32].
Potential of aldosterone antagonists
in atrial fibrillation prevention:
Experimental and clinical studies
All of the above mentioned mechanisms, espe-
cially electrolyte and autonomic imbalance and the
severity of fibrosis, affect the environment of the
arrhythmias and increase the risk of AF. Patients
with primary aldosteronism have an average 12-fold
higher risk of AF [33]. It was shown that ALD con-
centration increases during AF [34]. Plasma aldos-
terone-receptor expression is higher in atria of AF
patients [35]. Myocardial fibrosis is particularly
important in the impairment of myocardium func-
tion and as a substrate for arrhythmias. Fibrotic tis-
sue, with a low voltage, may be a potential cause of
atrial activation disturbances that may be involved
in AF occurrence and maintenance [36]. Experi-
mentally-induced fibrosis in an animal model result-
ed in a greater likelihood of AF [37]. Atrial tissue
samples from patients with AF also showed in-
creased fibrosis [38]. Rapidly stimulated cardiomyo-
cytes during AF secrete substances that increase
collagen and fibronectin-1 in atrial tissue by a fac-
tor of four [39]. Frequent episodes of AF exacer-
bate fibrosis which increases the risk of further
seizures. Spatial distribution and the extent of fi-
brotic tissues of low voltage has a significant im-
pact on the fibrillatory dynamics of contraction, in-
cluding the location and propagation of fibrillation
waves [40]. It is likely that the processes of fibro-
sis and remodeling contribute to the formation of
Table 2. Deleterious actions of aldosterone.




Sodium retention, loss of potassium and magnesium
Catecholamine potentiation
Ventricular arrhythmias
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re-entry circuits sustaining arrhythmia [41]. The
reduction of myocardial tissue strain and the short-
ening of the effective refractory period may be re-
sponsible for changes of the electrical activity. Pre-
liminary results show that the success of pulmonary
vein isolation during ablation is limited by the pres-
ence of fibrotic tissue with a low voltage or scars
[42, 43]. Histological examinations confirmed the
presence of fibrosis in tissues with a low voltage,
but the assessment of their extent and severity is
difficult [44]. Magnetic resonance imaging (MRI)
with late enhancement is a good method to assess
fibrosis and tissue remodeling. Marrouche at al. [45]
of the University of Utah Health Sciences Center
has published several reports on the role of mag-
netic resonance imaging in the evaluation of the
anatomy of the myocardium structure in terms of
prevalence of atrial fibrosis. Multivariate analysis
demonstrated that the area of late enhancement of
the walls of the left atrium (LA) in MRI correlates
with the severity of AF. These studies suggest that
the success of ablation depend on the extent of fi-
brosis within the atria. Scope of degenerative chang-
es is assessed in the study of magnetic resonance
delayed enhancement (DE-MRI), in which the test
is performed 10 min after administration of the con-
trast. This allows the assessment of tissue viabili-
ty and the degree of fibrosis. The UTAH scale was
created to assess the degree of atrial fibrosis on the
basis of DE-MRI: minimal — stage 1, < 5%, mild
— stage 2, 5–20%, moderate — stage 3, 20–35%,
and extensive — stage 4, > 35% [41, 45]. Exces-
sive enhancement in the walls of the LA indicates
substantial degree of fibrosis and also a high risk of
AF recurrence after ablation procedure [41].
In the experimental model of myocardial in-
farction only SPIR caused a reduction of fibrosis
within the atrial muscle and the shortening of the
P wave in ECG [33]. SPIR has been shown to re-
verse the effects of LA remodeling by reducing atri-
al hyperexcitability, inhibition of vascular Ang-I/
/Ang-II conversion and attenuation of atrial fibrosis
[46]. Therefore, there is enough evidence, from both
theoretical and experimental research studies, to
suggest that treatment of “upstream therapy” using
SPIR or eplerenone may reduce the deleterious ef-
fect of excess ALD secretion and, indirectly, ANG II,
and may also modify the environment of arrhythmias,
including inhibition of fibrosis (Table 3).
Goette at al. [34] demonstrated that AF occur-
rence results in an increase in ALD concentration,
and 2 days after cardioversion its level declines with
the reduction of aldosterone–renine index and mean
heart rate. In an experimental study, atenolol, lisi-
nopril and SPIR effects were evaluated for 3 months
after heart infarction. Only SPIR generated a reduc-
tion of atrial fibrosis and a reduction of P wave ac-
tivity in ECG [47]. These two factors are among the
risk factors for AF episode occurrence. Thus, it is
logical that the up-stream therapy with SPIR can
further diminish a potentially harmful effect of ALD
and indirectly, ANG II, modifying the setting of
possible occurrence of arrhythmia. Arterial hyper-
tension is present in approximately 70% of AF pa-
tients. SPIR, having antihypertensive properties,
may have contributed to a better control of hyper-
tension, which can be of importance in its antiar-
rhythmic action. In some patients it may be either
alternative, i.e. supplementing or concomitant ther-
apy. Eplerenone, a novel selective ALD antagonist
may be a valuable alternative for a wider implemen-
tation of such a therapy in case of SPIR side effects,
especially gynecomastia occurrence.
Sub-analysis of the EMPHASIS study (eplero-
non in patients with mild systolic HF, NYHA II,
ejection fraction < 35%) indicated that the
eplerenone treatment can prevent first AF or atrial
flutter episode. In the study, 1,364 patients received
eplerenone at a dose of 25–50 mg, and 1,373 patients
received a placebo. The study was terminated af-
ter 21 months because of the 37% reduction in the
combined end point: 24% reduction in cardiovascu-
lar death and 42% reduction in hospitalization [48].
After 2 years of observation, newly-detected AF
occurred in 2.7% of patients treated with eplerenone
compared with 4.5% receiving placebo [49]. Single
Table 3. Possible beneficial effects of aldosterone
antagonists (spironolactone, eplerenone) in
prevention of atrial fibrillation.
Shortening of the P wave in ECG
Reduction of atrial hyperexcitability
Prevention of vascular endothelium changes
and oxidative stress
Attenuation of atrial fibrosis, reduction of
type I and III procolagen synthesis
Attenuation of volume overload of the left atrium




Prevention of cardiac remodeling: reduction of the
dimensions of the left atrium and both ventricles
Improvement of left ventricular function and
ejection fraction
Prevention of refractory paroxysmal and
persistent atrial fibrillation
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center, prospective, randomized SPIR-AF study
included patients (n = 164) with recurrent, paroxy-
smal or persistent AF, who did not responded to
treatment with conventional class I and III antiar-
rhythmic drugs or were intolerant to them. The
study demonstrated a reduction of AF episodes
during 12 months of treatment with SPIR and
a beta-blocker therapy, compared with enalapril and
a beta-blocker or the beta-blocker drug without the
use of antiarrhythmic drugs [50].
Prevention of left ventricle and atrial
remodeling in patients with chronic
atrial fibrillation: RAAS blockade
In chronic disease states such as arterial hy-
pertension and HF, AF may be a consequence of
pathological modulation of intercellular signals [51,
52]. Longer lasting AF causes structural changes
within the atria leading to increased activity of
dipeptidyl peptidase IV, and an increase in the ex-
pression of ANG-converting enzyme and ALD. At
the same time the levels of bradykinin decreases
[16]. The results of experimental studies in dogs
with HF (rapid ventricular pacing for 5 weeks)
showed that administration of enalapril reduces atri-
al fibrosis and heart remodeling and reduces the risk
of AF occurrence in HF, which indicates the role of
the RAAS system in remodeling of the atria [31].
In another study in dogs undergoing rapid ventri-
cular pacing to induce HF, administration of enala-
pril resulted in decreases in conduction heteroge-
neity and reduced AF duration and degree of fibro-
sis within the atria [55]. Potentially beneficial effects
of ACE-I and ARB is to prevent adverse changes
within the ion channels, stabilization of electrolyte
concentration, prevention of overloading the cells
with calcium ions and reduce the degree of atrial
wall stretch, end-diastolic pressure reduction in the
left ventricle and the prevention of cardiac fibrosis
[21]. Chronic AF is a permanent arrhythmia which
in longer period promotes electrical and structural
remodeling of atria and ventricles [53, 54]. AF it-
self perpetuates the development of structural atrial
alterations by the increased expression of angio-
tensin converting enzyme, number of AT-1-recep-
tors in cardiomyocytes and ALD action. ANG II and
ALD promote the activation of fibroblasts and col-
lagen accumulation, which lead to atrial structural
and electrical remodeling [18]. Lack of the hemo-
dynamically effective systole of atria synchronized
with the systole of ventricles and a chaotic rhythm
of ventricles result in the volumetric overload of the
cardiac chambers, reduced diastolic filling and re-
duced stroke volume. These changes are followed
by a decrease in renal perfusion, activation of the
RAAS and adrenergic systems, increased vaso-
pressin, ANG II and ALD secretion. ALD concen-
trations are elevated in patients with persistent AF
[34]. Long lasting AF leads to interstitial fibrosis,
monocytic infiltration, degeneration and atrophy of
atrial myocytes, atrial and ventricular remodeling
and, finally, to HF. Reports suggests that suppres-
sion of RAAS activity by ACE-inhibitors may inhibit
atrial and ventricular remodeling [10, 55]. SPIR may
prevent cardiac remodeling via the ACE, epidermal
growth factor receptor (EGFR), extracellular sig-
nal-regulated kinases (ERK) pathway, nicotinamide
adenine dinucleotide phosphate oxidase, lectin-like
oxidized low-density lipoprotein receptor-1 and
Rho-kinase pathways [56]. SPIR has an early gene-
-regulatory effect independent of MR. The affected
genes encode a large number of signaling proteins
and receptors, including immunoinflammatory re-
sponse genes, apoptosis and antiapoptosis genes.
The results indicate that SPIR affects genes con-
trolled by the transcription factors NF-kappaB,
CEBPbeta and MYC [57]. SPIR protects from
caspase-3 activation induced by serum deprivation
in contrast to the selective MR antagonist,
eplerenone, that is non-protective. Progesterone,
hydrocortisone and dexamethasone all protect hu-
man umbilical vein endothelial cells from serum-
deprivation induced caspase-3 activation, whereas
ALD and dihydrotestosterone had no effect. SPIR
displayed agonist activity only to the progesterone
receptor. SPIR and progesterone, but not eplerenone,
inhibited mitochondrial cytochrome c release and
cleavage of nuclear poly (ADP-ribose) polymerase
(PARP) by a NO-independent mechanism and in-
creased cell viability. This effect is likely mediated
by the agonist properties of SPIR toward the
progesterone receptor [58].
Experimental and clinical studies showed
a beneficial effect of ALD receptors antagonists on
the inhibition of heart and arterial remodeling in
arterial hypertension [59, 60]. The RALES land-
mark study showed a significant reduction of the
morbidity and risk after 24 months of blocking ALD
receptors by SPIR among patients with severe HF
[61]. In patients after myocardial infarction, SPIR
and potassium canrenoate treatment resulted in the
reduction of type I and III procolagen synthesis and
inhibition of left ventricular dilation [62, 63]. Dilat-
ed left atria and fibrosis may be a direct conse-
quence of left ventricle dysfunction and hemody-
namic atrial overload. In the study by Milliez et al.
[47], SPIR, an ALD antagonist, was introduced
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three months after myocardial infarction, when atri-
al remodeling had developed. The effect of the treat-
ment was insignificant after one month of therapy,
but SPIR reduced the fibrosis of dilated atria in the
course of HF. Apart from fibrosis inhibition, an im-
portant factor may be the attenuation of volume
overload of the LA, electrolyte and autonomic ba-
lance stabilization. It is possible that ALD, apart from
influencing indirectly on the AF development, may
exert a further augmented action on the remodel-
ing of atria and ventricles in the vicious circle mech-
anism according to the statement that “AF begets
AF” [1, 64]. Long lasting AF leads to atrial and ven-
tricular remodeling followed by HF, so early preven-
tion with an ALD antagonist, SPIR or eplerenone,
may be justified. SPIR has been shown to reverse
the effects of LA remodeling by reducing atrial hy-
perexcitability, inhibition of vascular Ang-I/Ang-II
conversion and attenuation of atrial fibrosis [65]. In
an experimental study, three groups of dogs (n = 21)
had right atrial pacing for 6 weeks. The group was
given SPIR one week before, and during, the atrial
pacing. Myolisis, atrial fibrosis and dilatation were
all significantly increased and these changes were
inhibited by SPIR. SPIR treatment reversed the in-
creased expression of caspase-3, bax, calpain I and
MMP-9 and the decreased level of Bcl-2, calpasta-
tin and TIMP-1, induced by chronic atrial pacing
[66]. SPIR can prevent vascular changes and oxi-
datative stress [67]. Eight genes have been identi-
fied whose expression is regulated by ALD, and
which are involved in the process of remodeling the
left atria and the regulation of vascular tone [68].
Clinical reports show that long lasting therapy with
SPIR at 25 mg/day may result in a significant re-
duction of the dimensions of the LA and both ven-
tricles in patients with chronic AF. In a meta-ana-
lysis of 19 randomized trials evaluating the treat-
ment of ALD antagonists, SPIR, eplerenone, or
potassium kanreonate of heterogeneous groups of
patients with left ventricular dysfunction, 20% re-
duction in overall mortality and 3.1% improvement
in left ventricular ejection fraction was observed
[69]. Results of the study using an experimental
model of heart infarct in rats showed that eplerenone,
added to irbesartan, caused the improvement of left
ventricular function and inhibited its remodeling
[70]. Patients with chronic heart failure (n = 51),
NYHA class I–III, ejection fraction < 40%, were
randomized to treatment of SPIR, candesartan vs
placebo. MRI demonstrated significant improve-
ment in left ventricular ejection fraction (35 vs 26%,
p < 0.01) and other parameters evaluated in tissue
Doppler in patients treated with two drugs, indicat-
ing inhibition of left ventricular remodeling [71].
Recently some papers addressed the issue of
aldosterone-receptor antagonism as a potential
therapeutic target in prevention and regulation of
AF [72, 73].
Conclusions
Aldosterone antagonists treatment may be
a simple and valuable additional option in low-risk,
hypertensive and HF patients in primary and se-
condary prevention of refractory paroxysmal and
persistent AF. In patients with chronic AF aldos-
terone antagonists can suppress atrial and ventri-
cular remodeling.
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